K
Katrin Sangkuhl
Researcher at Stanford University
Publications - 78
Citations - 10389
Katrin Sangkuhl is an academic researcher from Stanford University. The author has contributed to research in topics: Pharmacogenetics & Pharmacogenomics. The author has an hindex of 35, co-authored 69 publications receiving 7909 citations. Previous affiliations of Katrin Sangkuhl include Free University of Berlin & University of Oulu.
Papers
More filters
Journal ArticleDOI
Pharmacogenomics Knowledge for Personalized Medicine
Michelle Whirl-Carrillo,Ellen M. McDonagh,Joan M. Hebert,Li Gong,Katrin Sangkuhl,Caroline F. Thorn,Russ B. Altman,Teri E. Klein +7 more
TL;DR: The Pharmacogenomics Knowledgebase is a useful source of high‐quality information supporting personalized medicine–implementation projects.
Journal ArticleDOI
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Stuart A. Scott,Katrin Sangkuhl,Charles M. Stein,Jean-Sébastien Hulot,Jean-Sébastien Hulot,Jessica L. Mega,Dan M. Roden,Teri E. Klein,Marc S. Sabatine,Julie A. Johnson,Julie A. Johnson,Alan R. Shuldiner,Alan R. Shuldiner +12 more
TL;DR: In this article, an expanded literature review showed that CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI).
Journal ArticleDOI
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
JK Hicks,Jeffrey R. Bishop,Katrin Sangkuhl,Daniel J. Müller,Yuan Ji,SG Leckband,J. S. Leeder,Rebecca L. Graham,DL Chiulli,Adrián LLerena,Todd C. Skaar,Stuart A. Scott,Julia C. Stingl,Teri E. Klein,Kelly E. Caudle,Andrea Gaedigk +15 more
TL;DR: Evidence from the published literature supporting associations between CYP2D6 and CYC19 polymorphisms and SSRIs efficacy and safety is summarized and dosing recommendations for fluvoxamine, paroxetine, citalopram, escitaloprams, and sertraline based on CYP1C19 genotype are provided.
Journal ArticleDOI
Clinical assessment incorporating a personal genome
Euan A. Ashley,Atul J. Butte,Matthew T. Wheeler,Rong Chen,Teri E. Klein,Frederick E. Dewey,Joel T. Dudley,Kelly E. Ormond,Aleksandra Pavlovic,Alexander A. Morgan,Dmitry Pushkarev,Norma F. Neff,Louanne Hudgins,Li Gong,Laura M. Hodges,Dorit S. Berlin,Caroline F. Thorn,Katrin Sangkuhl,Joan M. Hebert,Mark Woon,Hersh Sagreiya,Ryan Whaley,Joshua W. Knowles,Michael F. Chou,Joseph V. Thakuria,Abraham M. Rosenbaum,Alexander Wait Zaranek,George M. Church,Henry T. Greely,Stephen R. Quake,Russ B. Altman +30 more
TL;DR: Although challenges remain, the results suggest that whole-genome sequencing can yield useful and clinically relevant information for individual patients.
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic
TL;DR: Evidence from published literature is presented for CYP 2D6 and CYP2C19 genotype–directed dosing of tricyclic antidepressants.